There are 2789 resources available
177P - Pathogenicity reclassification of unknown significance variants related to early-onset breast cancer women of mongoloid origin
Presenter: Polina Gervas
Session: ePoster Display
178P - Age-related mutational landscape of luminal breast cancers
Presenter: Nawale Hajjaji
Session: ePoster Display
179P - Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin for early triple-negative breast cancer: A single-arm, open-label, phase II study
Presenter: Chengzheng Wang
Session: ePoster Display
180P - Relapse pattern after neoadjuvant treatment in early breast cancer
Presenter: Ariadna Gasol Cudos
Session: ePoster Display
181P - Pegylated liposomal doxorubicin (PLD) combined with docetaxel and trastuzumab in neoadjuvant treatment for HER2-positive breast cancer: A multicenter, randomized, phase II, open-label trial
Presenter: Zhenchuan Song
Session: ePoster Display
182P - Correlation between TILs, ALDH1 and PD-L1 expression in triple-negative (TN) and HER2-positive (HER2+) breast cancer (BC)
Presenter: Mariana Lopez
Session: ePoster Display
183P - Clinical treatment score post-5 years (CTS5) as a tool for risk estimation of late recurrence in Thai patients with estrogen receptor positive, early breast cancer: A validation study
Presenter: Panchanin Patanayindee
Session: ePoster Display
184P - Prognostic value of geriatric screening tools compared to Balducci criteria on deterioration free survival in elderly patients (pts) with early-stage breast cancer (BC)
Presenter: Irene Paredero Perez
Session: ePoster Display
236P - Real-world comparative effectiveness of palbociclib plus letrozole vs letrozole in older patients with metastatic breast cancer
Presenter: Hope Rugo
Session: ePoster Display
Resources:
Abstract
Slides
237P - Real-world outcomes of hormone receptor-positive (HR+) HER2-negative (HER2-) metastatic breast cancer (mBC) with high tumor mutational burden (hTMB) treated with immune checkpoint inhibitors (ICI)
Presenter: Saranya Chumsri
Session: ePoster Display